Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

547
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
547
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.1K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biology and Time Course of Obstruction-Induced Detrusor Underactivity Causing Postvoid Residual Urine.

International neurourology journal·2026
Same author

Bladder under stress: Pathological and adaptive shifts in channel expression.

Channels (Austin, Tex.)·2026
Same author

Erectile and Clitoral Dysfunction as Harbingers of Cardiovascular Disease: A Perspective.

Medicina (Kaunas, Lithuania)·2026
Same author

Endogenous vasopressin and vasopressin receptor 2 in bladder as anti-diuretic / anti-spasmodic targets for the treatment of multifactorial nocturia.

Continence (Amsterdam, Netherlands)·2026
Same author

Prevalence, Socioeconomic, and Environmental Costs of Urinary Incontinence in the European Union.

European urology·2025
Same author

Urethral pharmacological mechanisms incontinence and bladder emptying: An updated review.

Bladder (San Francisco, Calif.)·2024

Related Experiment Video

Updated: Feb 14, 2026

Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.9K

Pharmacotherapy for Nocturia.

Karl-Erik Andersson1,2,3, Philip Van Kerrebroeck4

  • 1Lund University, Lund, Sweden. karl-erik.andersson@med.lu.se.

Current Urology Reports
|February 11, 2018
PubMed
Summary

Current treatments for nocturia (frequent nighttime urination) and nocturnal polyuria (excessive nighttime urine production) are often insufficient. Personalized treatment based on underlying causes is key, but new drugs are needed.

Keywords:
Global polyuriaNocturnal polyuriaOveractive bladderPharmacological principlesReduced bladder capacity

More Related Videos

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.7K
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.9K

Related Experiment Videos

Last Updated: Feb 14, 2026

Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.9K
Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.7K
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.9K

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Nocturia and nocturnal polyuria are common conditions with multifactorial pathophysiology.
  • Current pharmacological treatments primarily target daytime symptoms of lower urinary tract symptoms (LUTS) and overactive bladder (OAB), with limited efficacy for nocturia.

Purpose of the Study:

  • To assess current pharmacological principles for treating nocturia and nocturnal polyuria.
  • To evaluate the effectiveness of existing drug classes for nocturia management.

Main Methods:

  • Review of current literature on pharmacological interventions for nocturia.
  • Analysis of drug efficacy based on underlying pathophysiological mechanisms (low functional bladder capacity, nocturnal polyuria).

Main Results:

  • Nocturia treatment is challenging due to multifactorial causes, often requiring personalized approaches.
  • Existing medications for LUTS and OAB show limited success in treating nocturia compared to daytime symptoms.
  • Pharmacological strategies should target specific mechanisms like detrusor overactivity or nocturnal polyuria.

Conclusions:

  • Effective nocturia treatment necessitates addressing the primary etiological factors, including bladder capacity and nocturnal urine production.
  • Personalized treatment plans considering gender, comorbidities, and specific causes are recommended.
  • There is a significant unmet medical need for novel, approved pharmacological agents specifically for nocturia treatment.